{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:36:39Z","timestamp":1791293799806,"version":"4.1.0"},"reference-count":262,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TEVA\u00a0 (the NNE program)"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Mutation"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1002\/humu.23056","type":"journal-article","created":{"date-parts":[[2016,7,23]],"date-time":"2016-07-23T09:02:39Z","timestamp":1469264559000},"page":"1121-1136","source":"Crossref","is-referenced-by-count":29,"title":["New Directions in Gaucher Disease"],"prefix":"10.1155","volume":"37","author":[{"given":"Mia","family":"Horowitz","sequence":"first","affiliation":[{"name":"Department of Cell Research and Immunology, Faculty of Life Sciences; Tel Aviv University; Ramat Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Elstein","sequence":"additional","affiliation":[{"name":"Gaucher Clinic; Shaare Zedek Medical Center; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[{"name":"Gaucher Clinic; Shaare Zedek Medical Center; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[{"name":"Lysosomal Disorders Unit, O&O ALPAN LLC; Fairfax Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,21]]},"reference":[{"key":"10.1002\/humu.23056-BIB0001|humu23056-cit-0001","doi-asserted-by":"crossref","first-page":"839","DOI":"10.15252\/embr.201439076","article-title":"Getting ready for building: signaling and autophagosome biogenesis","volume":"15","author":"Abada","year":"2014","journal-title":"EMBO Rep"},{"key":"10.1002\/humu.23056-BIB0002|humu23056-cit-0002","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/mp200313e","article-title":"Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase","volume":"8","author":"Abian","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1002\/humu.23056-BIB0003|humu23056-cit-0003","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(95)91688-1","article-title":"Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype","volume":"346","author":"Abrahamov","year":"1995","journal-title":"Lancet"},{"key":"10.1002\/humu.23056-BIB0004|humu23056-cit-0004","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/acel.12409","article-title":"Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages","volume":"15","author":"Aflaki","year":"2016","journal-title":"Aging Cell"},{"key":"10.1002\/humu.23056-BIB0005|humu23056-cit-0005","doi-asserted-by":"crossref","first-page":"240ra273","DOI":"10.1126\/scitranslmed.3008659","article-title":"Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs","volume":"6","author":"Aflaki","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1002\/humu.23056-BIB0006|humu23056-cit-0006","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1039\/c1ob05234a","article-title":"Bicyclic (galacto)nojirimycin analogues as glycosidase inhibitors: effect of structural modifications in their pharmacological chaperone potential towards beta-glucocerebrosidase","volume":"9","author":"Aguilar-Moncayo","year":"2011","journal-title":"Org Biomol Chem"},{"key":"10.1002\/humu.23056-BIB0007|humu23056-cit-0007","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1039\/c2cc32065g","article-title":"Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis","volume":"48","author":"Aguilar-Moncayo","year":"2012","journal-title":"Chem Commun (Camb)"},{"key":"10.1002\/humu.23056-BIB0008|humu23056-cit-0008","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa033277","article-title":"Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews","volume":"351","author":"Aharon-Peretz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/humu.23056-BIB0009|humu23056-cit-0009","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/13803390903521018","article-title":"Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease","volume":"32","author":"Alcalay","year":"2010","journal-title":"J Clin Exp Neuropsychol"},{"key":"10.1002\/humu.23056-BIB0010|humu23056-cit-0010","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcmd.2005.05.007","article-title":"Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations","volume":"35","author":"Alfonso","year":"2005","journal-title":"Blood Cells Mol Dis"},{"key":"10.1002\/humu.23056-BIB0011|humu23056-cit-0011","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0021-9258(17)34875-5","article-title":"Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells","volume":"253","author":"Alt","year":"1978","journal-title":"J Biol Chem"},{"key":"10.1002\/humu.23056-BIB0012|humu23056-cit-0012","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1750-1172-6-66","article-title":"Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests","volume":"6","author":"Andreotti","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1002\/humu.23056-BIB0013|humu23056-cit-0013","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1371\/journal.pone.0004792","article-title":"A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation","volume":"4","author":"Aviezer","year":"2009","journal-title":"PLoS One"},{"key":"10.1002\/humu.23056-BIB0014|humu23056-cit-0014","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1093\/hmg\/ddv297","article-title":"Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells","volume":"24","author":"Awad","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0015|humu23056-cit-0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ymgme.2012.04.018","article-title":"Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant beta-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant","volume":"106","author":"Babajani","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1002\/humu.23056-BIB0016|humu23056-cit-0016","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1038\/emm.2015.84","article-title":"Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and alpha-synuclein aggregation","volume":"47","author":"Bae","year":"2015","journal-title":"Exp Mol Med"},{"key":"10.1002\/humu.23056-BIB0017|humu23056-cit-0017","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1093\/hmg\/ddn124","article-title":"A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome","volume":"17","author":"Balreira","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0018|humu23056-cit-0018","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJM199305273282112","article-title":"Treatment of Gaucher's disease","volume":"328","author":"Barton","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1002\/humu.23056-BIB0019|humu23056-cit-0019","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamaneurol.2014.2950","article-title":"Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort","volume":"72","author":"Beavan","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1002\/humu.23056-BIB0020|humu23056-cit-0020","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/07853890.2013.849003","article-title":"Glucocerebrosidase mutations and the pathogenesis of Parkinson disease","volume":"45","author":"Beavan","year":"2013","journal-title":"Ann Med"},{"key":"10.1002\/humu.23056-BIB0021|humu23056-cit-0021","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.WNL.0000072482.70963.D7","article-title":"Gaucher's disease with Parkinson's disease: clinical and pathological aspects","volume":"61","author":"Bembi","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/humu.23056-BIB0022|humu23056-cit-0022","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"Bendikov-Bar","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"10.1002\/humu.23056-BIB0023|humu23056-cit-0023","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1750-1172-9-86","article-title":"Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS","volume":"9","author":"Bendikov-Bar","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1002\/humu.23056-BIB0024|humu23056-cit-0024","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/13543776.2011.569162","article-title":"Pharmacological chaperone therapy for Gaucher disease: a patent review","volume":"21","author":"Benito","year":"2011","journal-title":"Expert Opin Ther Pat"},{"key":"10.1002\/humu.23056-BIB0025|humu23056-cit-0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ymgme.2014.05.009","article-title":"Pharmacological chaperones increase residual \u03b2-galactocerebrosidase activity in fibroblasts from Krabbe patients","volume":"112","author":"Berardi","year":"2014","journal-title":"Mol Genet Metab"},{"key":"10.1002\/humu.23056-BIB0026|humu23056-cit-0026","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1432-1033.1993.tb17749.x","article-title":"Involvement of the 20S proteasome in the degradation of ornithine decarboxylase","volume":"213","author":"Bercovich","year":"1993","journal-title":"Eur J Biochem"},{"key":"10.1002\/humu.23056-BIB0027|humu23056-cit-0027","doi-asserted-by":"crossref","first-page":"14861","DOI":"10.1016\/S0021-9258(18)82412-7","article-title":"Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity","volume":"268","author":"Berg-Fussman","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1002\/humu.23056-BIB0028|humu23056-cit-0028","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF01931089","article-title":"Gaucher disease, a paradigm for single gene defects","volume":"51","author":"Beutler","year":"1995","journal-title":"Experientia"},{"key":"10.1002\/humu.23056-BIB0029|humu23056-cit-0029","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lab.2004.03.013","article-title":"Mutations in the gene encoding cytosolic beta-glucosidase in Gaucher disease","volume":"144","author":"Beutler","year":"2004","journal-title":"J Lab Clin Med"},{"key":"10.1002\/humu.23056-BIB0030|humu23056-cit-0030","first-page":"3635","volume-title":"The metabolic and molecular basis of inherited diseases","author":"Beutler","year":"2001"},{"key":"10.1002\/humu.23056-BIB0031|humu23056-cit-0031","doi-asserted-by":"crossref","first-page":"7472","DOI":"10.1073\/pnas.83.19.7472","article-title":"Glucocerebrosidase processing in normal fibroblasts and in fibroblasts from patients with Type I, Type II, and Type III Gaucher disease","volume":"83","author":"Beutler","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0032|humu23056-cit-0032","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1074\/jbc.M610544200","article-title":"Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2","volume":"282","author":"Boot","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1002\/humu.23056-BIB0033|humu23056-cit-0033","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.biocel.2011.12.005","article-title":"X-linked inhibitor of apoptosis protein promotes the degradation of its antagonist, the pro-apoptotic arts protein","volume":"44","author":"Bornstein","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1002\/humu.23056-BIB0034|humu23056-cit-0034","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00415-013-7011-2","article-title":"Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease","volume":"260","author":"Bottcher","year":"2013","journal-title":"J Neurol"},{"key":"10.1002\/humu.23056-BIB0035|humu23056-cit-0035","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1021\/jm301557k","article-title":"Pharmacological chaperones as therapeutics for lysosomal storage diseases","volume":"56","author":"Boyd","year":"2013","journal-title":"J Med Chem"},{"key":"10.1002\/humu.23056-BIB0036|humu23056-cit-0036","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1016\/j.bmcl.2014.04.108","article-title":"Correction of lysosomal dysfunction as a therapeutic strategy for neurodegenerative diseases","volume":"24","author":"Boyd","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1002\/humu.23056-BIB0037|humu23056-cit-0037","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.26071","article-title":"GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study","volume":"30","author":"Brockmann","year":"2015","journal-title":"Mov Disord"},{"key":"10.1002\/humu.23056-BIB0038|humu23056-cit-0038","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1039\/c1ob05200d","article-title":"Cyclodextrin-mediated crystallization of acid beta-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues","volume":"9","author":"Brumshtein","year":"2011","journal-title":"Org Biomol Chem"},{"key":"10.1002\/humu.23056-BIB0039|humu23056-cit-0039","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2010","journal-title":"Glycobiology"},{"key":"10.1002\/humu.23056-BIB0040|humu23056-cit-0040","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cbpa.2007.05.035","article-title":"Gaucher disease","volume":"11","author":"Butters","year":"2007","journal-title":"Curr Opin Chem Biol"},{"key":"10.1002\/humu.23056-BIB0041|humu23056-cit-0041","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1007\/s00018-008-8119-x","article-title":"P63 in epithelial development","volume":"65","author":"Candi","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1002\/humu.23056-BIB0042|humu23056-cit-0042","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1021\/jm3006178","article-title":"Conformationally-locked N-glycosides with selective beta-glucosidase inhibitory activity: identification of a new non-iminosugar-type pharmacological chaperone for Gaucher disease","volume":"55","author":"Castilla","year":"2012","journal-title":"J Med Chem"},{"key":"10.1002\/humu.23056-BIB0043|humu23056-cit-0043","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1111\/j.1742-4658.2006.05410.x","article-title":"Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients","volume":"273","author":"Chang","year":"2006","journal-title":"FEBS J"},{"key":"10.1002\/humu.23056-BIB0044|humu23056-cit-0044","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1016\/j.bmc.2013.06.054","article-title":"Rapid modifications of N-substitution in iminosugars: development of new beta-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease","volume":"21","author":"Cheng","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1002\/humu.23056-BIB0045|humu23056-cit-0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","article-title":"Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies","volume":"10","author":"Chiasserini","year":"2015","journal-title":"Mol Neurodegener"},{"key":"10.1002\/humu.23056-BIB0046|humu23056-cit-0046","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12035-013-8605-5","article-title":"Chaperone therapy for GM2 gangliosidosis: effects of pyrimethamine on beta-hexosaminidase activity in Sandhoff fibroblasts","volume":"50","author":"Chiricozzi","year":"2014","journal-title":"Mol Neurobiol"},{"key":"10.1002\/humu.23056-BIB0047|humu23056-cit-0047","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm1001-1144","article-title":"Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease","volume":"7","author":"Chung","year":"2001","journal-title":"Nat Med"},{"key":"10.1002\/humu.23056-BIB0048|humu23056-cit-0048","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archneurol.2009.54","article-title":"Association of glucocerebrosidase mutations with dementia with Lewy bodies","volume":"66","author":"Clark","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1002\/humu.23056-BIB0049|humu23056-cit-0049","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/mds.20320","article-title":"Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity","volume":"20","author":"Clark","year":"2005","journal-title":"Mov Disord"},{"key":"10.1002\/humu.23056-BIB0050|humu23056-cit-0050","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.wnl.0000276989.17578.02","article-title":"Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease","volume":"69","author":"Clark","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/humu.23056-BIB0051|humu23056-cit-0051","doi-asserted-by":"crossref","first-page":"17400","DOI":"10.1073\/pnas.1203924109","article-title":"Pharmacological chaperones for human alpha-n-acetylgalactosaminidase","volume":"109","author":"Clark","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0052|humu23056-cit-0052","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/hmg\/ddg159","article-title":"The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration","volume":"12","author":"Corti","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0053|humu23056-cit-0053","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1002\/humu.23056-BIB0258|humu23056-cit-0258","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/humu.23056-BIB0054|humu23056-cit-0054","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/cr.2013.153","article-title":"Chaperone-mediated autophagy: roles in disease and aging","volume":"24","author":"Cuervo","year":"2014","journal-title":"Cell Res"},{"key":"10.1002\/humu.23056-BIB0055|humu23056-cit-0055","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1002\/humu.23056-BIB0056|humu23056-cit-0056","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/mt.2015.16","article-title":"Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice","volume":"23","author":"Dahl","year":"2015","journal-title":"Mol Ther"},{"key":"10.1002\/humu.23056-BIB0057|humu23056-cit-0057","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.stem.2009.02.009","article-title":"Broader implications of defining standards for the pluripotency of iPSCs","volume":"4","author":"Daley","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1002\/humu.23056-BIB0058|humu23056-cit-0058","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fnmol.2014.00070","article-title":"The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution","volume":"7","author":"Dantuma","year":"2014","journal-title":"Front Mol Neurosci"},{"key":"10.1002\/humu.23056-BIB0059|humu23056-cit-0059","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbrc.2010.03.137","article-title":"Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease","volume":"395","author":"Dawson","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1002\/humu.23056-BIB0060|humu23056-cit-0060","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1042\/bj3560907","article-title":"Cloning and characterization of human liver cytosolic beta-glycosidase","volume":"356","author":"Graaf","year":"2001","journal-title":"Biochem J"},{"key":"10.1002\/humu.23056-BIB0061|humu23056-cit-0061","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2174\/138920111795542651","article-title":"Mucopolysaccharidosis type III (Sanfilippo syndrome): emerging treatment strategies","volume":"12","author":"Ruijter","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1002\/humu.23056-BIB0062|humu23056-cit-0062","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bcmd.2010.07.009","article-title":"The cytosolic beta-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation","volume":"46","author":"Dekker","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1002\/humu.23056-BIB0063|humu23056-cit-0063","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1212\/WNL.38.8.1237","article-title":"Olfactory dysfunction in Parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration","volume":"38","author":"Doty","year":"1988","journal-title":"Neurology"},{"key":"10.1002\/humu.23056-BIB0064|humu23056-cit-0064","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1080\/15548627.2015.1086055","article-title":"GBA deficiency promotes SNCA\/alpha-synuclein accumulation through autophagic inhibition by inactivated PPP2A","volume":"11","author":"Du","year":"2015","journal-title":"Autophagy"},{"key":"10.1002\/humu.23056-BIB0065|humu23056-cit-0065","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/mds.25248","article-title":"The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease","volume":"28","author":"Duran","year":"2013","journal-title":"Mov Disord"},{"key":"10.1002\/humu.23056-BIB0066|humu23056-cit-0066","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2006.05.032","article-title":"Glucocerebrosidase mutations are not found in association with LRKK2 G2019S in subjects with Parkinsonism","volume":"404","author":"Eblan","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1002\/humu.23056-BIB0067|humu23056-cit-0067","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1158\/1078-0432.CCR-11-1430","article-title":"Peptides mimicking the unique ARTS-XIAP binding site promote apoptotic cell death in cultured cancer cells","volume":"18","author":"Edison","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1002\/humu.23056-BIB0068|humu23056-cit-0068","doi-asserted-by":"crossref","first-page":"14319","DOI":"10.1016\/S0021-9258(17)38720-3","article-title":"Biosynthesis of the lysosomal enzyme glucocerebrosidase","volume":"260","author":"Erickson","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1002\/humu.23056-BIB0069|humu23056-cit-0069","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/hmg\/ddp061","article-title":"No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease","volume":"18","author":"Farfel-Becker","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0070|humu23056-cit-0070","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1242\/dmm.008185","article-title":"Animal models for Gaucher disease research","volume":"4","author":"Farfel-Becker","year":"2011","journal-title":"Dis Model Mech"},{"key":"10.1002\/humu.23056-BIB0071|humu23056-cit-0071","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1093\/brain\/awu291","article-title":"Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation","volume":"137","author":"Fishbein","year":"2014","journal-title":"Brain"},{"key":"10.1002\/humu.23056-BIB0072|humu23056-cit-0072","doi-asserted-by":"crossref","first-page":"e16734","DOI":"10.1371\/journal.pone.0016734","article-title":"Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A","volume":"6","author":"Fujiwara","year":"2011","journal-title":"PLoS One"},{"key":"10.1002\/humu.23056-BIB0073|humu23056-cit-0073","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/cdd.2011.96","article-title":"Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012","volume":"19","author":"Galluzzi","year":"2012","journal-title":"Cell Death Differ"},{"key":"10.1002\/humu.23056-BIB0074|humu23056-cit-0074","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1212\/01.wnl.0000304039.11891.29","article-title":"Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset","volume":"70","author":"Gan-Or","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/humu.23056-BIB0075|humu23056-cit-0075","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1194\/jlr.M043802","article-title":"Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis","volume":"55","author":"Gaspar","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1002\/humu.23056-BIB0076|humu23056-cit-0076","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1002\/humu.23056-BIB0077|humu23056-cit-0077","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nbd.2015.09.006","article-title":"Mitochondrial dysfunction associated with glucocerebrosidase deficiency","volume":"90","author":"Gegg","year":"2016","journal-title":"Neurobiol Dis"},{"issue":"Suppl 1","key":"10.1002\/humu.23056-BIB0078|humu23056-cit-0078","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1002\/humu.23056-BIB0079|humu23056-cit-0079","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1073\/pnas.79.18.5607","article-title":"Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease","volume":"79","author":"Ginns","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0080|humu23056-cit-0080","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1073\/pnas.82.20.7101","article-title":"Gene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for Gaucher disease","volume":"82","author":"Ginns","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0081|humu23056-cit-0081","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/physrev.00027.2001","article-title":"The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction","volume":"82","author":"Glickman","year":"2002","journal-title":"Physiol Rev"},{"key":"10.1002\/humu.23056-BIB0082|humu23056-cit-0082","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1021\/jm201633y","article-title":"Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease","volume":"55","author":"Goddard-Borger","year":"2012","journal-title":"J Med Chem"},{"key":"10.1002\/humu.23056-BIB0083|humu23056-cit-0083","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1212\/01.wnl.0000230215.41296.18","article-title":"Glucocerebrosidase mutations are an important risk factor for Lewy body disorders","volume":"67","author":"Goker-Alpan","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/humu.23056-BIB0084|humu23056-cit-0084","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1136\/jmg.2004.028019","article-title":"Divergent phenotypes in Gaucher disease implicate the role of modifiers","volume":"42","author":"Goker-Alpan","year":"2005","journal-title":"J Med Genet"},{"key":"10.1002\/humu.23056-BIB0085|humu23056-cit-0085","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archneur.65.10.1353","article-title":"The spectrum of Parkinsonian manifestations associated with glucocerebrosidase mutations","volume":"65","author":"Goker-Alpan","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1002\/humu.23056-BIB0086|humu23056-cit-0086","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/brain\/aws174","article-title":"The neurobiology of glucocerebrosidase-associated Parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow","volume":"135","author":"Goker-Alpan","year":"2012","journal-title":"Brain"},{"key":"10.1002\/humu.23056-BIB0087|humu23056-cit-0087","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Goker-Alpan","year":"2004","journal-title":"J Med Genet"},{"key":"10.1002\/humu.23056-BIB0088|humu23056-cit-0088","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00401-010-0741-7","article-title":"Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders","volume":"120","author":"Goker-Alpan","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1002\/humu.23056-BIB0089|humu23056-cit-0089","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.emboj.7600155","article-title":"The mitochondrial arts protein promotes apoptosis through targeting xiap","volume":"23","author":"Gottfried","year":"2004","journal-title":"EMBO J"},{"key":"10.1002\/humu.23056-BIB0090|humu23056-cit-0090","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0950-3536(97)80032-7","article-title":"Gaucher's disease: molecular, genetic and enzymological aspects","volume":"10","author":"Grabowski","year":"1997","journal-title":"Baillieres Clin Haematol"},{"key":"10.1002\/humu.23056-BIB0091|humu23056-cit-0091","first-page":"600","article-title":"[Treatment of Gaucher disease: enzyme replacement therapy and emerging therapies (chemical chaperone and gene therapy)]","volume":"64","author":"Grosbois","year":"2006","journal-title":"Ann Biol Clin (Paris)"},{"key":"10.1002\/humu.23056-BIB0092|humu23056-cit-0092","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","article-title":"Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme","volume":"18","author":"Hollak","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1002\/humu.23056-BIB0093|humu23056-cit-0093","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0022-2275(20)39184-7","article-title":"Permeability barrier requirements regulate epidermal beta-glucocerebrosidase","volume":"35","author":"Holleran","year":"1994","journal-title":"J Lipid Res"},{"key":"10.1002\/humu.23056-BIB0094|humu23056-cit-0094","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/(SICI)1098-1004(1998)12:4<240::AID-HUMU4>3.0.CO;2-J","article-title":"Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population","volume":"12","author":"Horowitz","year":"1998","journal-title":"Hum Mutat"},{"key":"10.1002\/humu.23056-BIB0095|humu23056-cit-0095","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1002\/humu.23056-BIB0096|humu23056-cit-0096","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1097-2765(02)00583-X","article-title":"Chip is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity","volume":"10","author":"Imai","year":"2002","journal-title":"Mol Cell"},{"key":"10.1002\/humu.23056-BIB0097|humu23056-cit-0097","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0092-8674(01)00407-X","article-title":"An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin","volume":"105","author":"Imai","year":"2001","journal-title":"Cell"},{"key":"10.1002\/humu.23056-BIB0098|humu23056-cit-0098","doi-asserted-by":"crossref","first-page":"35661","DOI":"10.1074\/jbc.C000447200","article-title":"Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity","volume":"275","author":"Imai","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1002\/humu.23056-BIB0099|humu23056-cit-0099","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.4161\/auto.29642","article-title":"SREBF1 links lipogenesis to mitophagy and sporadic Parkinson disease","volume":"10","author":"Ivatt","year":"2014","journal-title":"Autophagy"},{"key":"10.1002\/humu.23056-BIB0100|humu23056-cit-0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cbic.201300442","article-title":"A systematic investigation of iminosugar click clusters as pharmacological chaperones for the treatment of Gaucher disease","volume":"15","author":"Joosten","year":"2014","journal-title":"Chembiochem"},{"key":"10.1002\/humu.23056-BIB0101|humu23056-cit-0101","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2009.01.029","article-title":"Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece","volume":"452","author":"Kalinderi","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1002\/humu.23056-BIB0102|humu23056-cit-0102","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1016\/j.bmc.2011.04.011","article-title":"Docking and SAR studies of D- and L-isofagomine isomers as human beta-glucocerebrosidase inhibitors","volume":"19","author":"Kato","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1002\/humu.23056-BIB0103|humu23056-cit-0103","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/mds.21105","article-title":"Side and type of motor symptom influence cognition in Parkinson's disease","volume":"21","author":"Katzen","year":"2006","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"10.1002\/humu.23056-BIB0104|humu23056-cit-0104","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1463-1326.2010.01281.x","article-title":"The unfolded protein response is required to maintain the integrity of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in beta-cells","volume":"12","author":"Kaufman","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1002\/humu.23056-BIB0105|humu23056-cit-0105","doi-asserted-by":"crossref","first-page":"e38837","DOI":"10.1371\/journal.pone.0038837","article-title":"Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein","volume":"7","author":"Kemeny","year":"2012","journal-title":"PLoS One"},{"key":"10.1002\/humu.23056-BIB0106|humu23056-cit-0106","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/brain\/awf237","article-title":"Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study","volume":"125","author":"Khan","year":"2002","journal-title":"Brain"},{"key":"10.1002\/humu.23056-BIB0107|humu23056-cit-0107","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1212\/01.WNL.0000118281.66802.81","article-title":"Olfaction differentiates parkin disease from early-onset Parkinsonism and Parkinson disease","volume":"62","author":"Khan","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/humu.23056-BIB0108|humu23056-cit-0108","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J"},{"key":"10.1002\/humu.23056-BIB0109|humu23056-cit-0109","doi-asserted-by":"crossref","first-page":"16193","DOI":"10.1074\/jbc.C600041200","article-title":"Identification of far upstream element-binding protein-1 as an authentic Parkin substrate","volume":"281","author":"Ko","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1002\/humu.23056-BIB0110|humu23056-cit-0110","doi-asserted-by":"crossref","first-page":"7968","DOI":"10.1523\/JNEUROSCI.2172-05.2005","article-title":"Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38\/JTV-1, leads to catecholaminergic cell death","volume":"25","author":"Ko","year":"2005","journal-title":"J Neurosci"},{"key":"10.1002\/humu.23056-BIB0111|humu23056-cit-0111","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0006-291X(05)81415-9","article-title":"Isolation and characterization of prosaposin from human milk","volume":"181","author":"Kondoh","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1002\/humu.23056-BIB0112|humu23056-cit-0112","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jns.2006.10.019","article-title":"Dopaminergic neuronal dysfunction associated with Parkinsonism in both a Gaucher disease patient and a carrier","volume":"252","author":"Kono","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1002\/humu.23056-BIB0113|humu23056-cit-0113","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/cbic.200800249","article-title":"Isofagomine induced stabilization of glucocerebrosidase","volume":"9","author":"Kornhaber","year":"2008","journal-title":"Chembiochem"},{"key":"10.1002\/humu.23056-BIB0114|humu23056-cit-0114","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1074\/jbc.M112.414714","article-title":"The non-lysosomal beta-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi","volume":"288","author":"Korschen","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1002\/humu.23056-BIB0115|humu23056-cit-0115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1242\/jcs.093567","article-title":"Non-canonical ubiquitin-based signals for proteasomal degradation","volume":"125","author":"Kravtsova-Ivantsiv","year":"2012","journal-title":"J Cell Sci"},{"key":"10.1002\/humu.23056-BIB0116|humu23056-cit-0116","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1152\/physiol.00050.2006","article-title":"Endoplasmic reticulum stress: signaling the unfolded protein response","volume":"22","author":"Lai","year":"2007","journal-title":"Physiology (Bethesda)"},{"key":"10.1002\/humu.23056-BIB0117|humu23056-cit-0117","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10822-009-9283-2","article-title":"Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase","volume":"23","author":"Landon","year":"2009","journal-title":"J Comput Aided Mol Des"},{"key":"10.1002\/humu.23056-BIB0118|humu23056-cit-0118","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/35046566","article-title":"A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif","volume":"2","author":"Larisch","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1002\/humu.23056-BIB0119|humu23056-cit-0119","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.bbrc.2011.08.080","article-title":"Protective effect of catechin in type I Gaucher disease cells by reducing endoplasmic reticulum stress","volume":"413","author":"Lee","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1002\/humu.23056-BIB0120|humu23056-cit-0120","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.bbadis.2007.02.003","article-title":"Enzyme enhancement activity of N-octyl-beta-valienamine on beta-glucosidase mutants associated with Gaucher disease","volume":"1772","author":"Lei","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/humu.23056-BIB0121|humu23056-cit-0121","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/hmg\/ddq454","article-title":"Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease","volume":"20","author":"Lesage","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0122|humu23056-cit-0122","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cbic.201300197","article-title":"New insights into the pharmacological chaperone activity of C2-substituted glucoimidazoles for the treatment of Gaucher disease","volume":"14","author":"Li","year":"2013","journal-title":"Chembiochem"},{"key":"10.1002\/humu.23056-BIB0123|humu23056-cit-0123","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"10.1002\/humu.23056-BIB0124|humu23056-cit-0124","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1002\/humu.23056-BIB0125|humu23056-cit-0125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbadis.2004.03.007","article-title":"N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease","volume":"1689","author":"Lin","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/humu.23056-BIB0126|humu23056-cit-0126","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.smim.2007.02.003","article-title":"The E3 ubiquitin ligase ITCH in T cell activation, differentiation, and tolerance","volume":"19","author":"Liu","year":"2007","journal-title":"Semin Immunol"},{"key":"10.1002\/humu.23056-BIB0127|humu23056-cit-0127","doi-asserted-by":"crossref","first-page":"21665","DOI":"10.1073\/pnas.1014376107","article-title":"Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl","volume":"107","author":"Lu","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0128|humu23056-cit-0128","doi-asserted-by":"crossref","first-page":"21200","DOI":"10.1073\/pnas.1119181109","article-title":"Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease","volume":"108","author":"Lu","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0259|humu23056-cit-0259","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. 2010","volume":"116","author":"Lukina","year":"2010a","journal-title":"Blood"},{"key":"10.1002\/humu.23056-BIB0260|humu23056-cit-0260","first-page":"5551","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 116: 4095-4098","volume":"117","author":"Lukina","year":"2010b","journal-title":"Correction in: Blood"},{"key":"10.1002\/humu.23056-BIB0261|humu23056-cit-0261","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol Dis."},{"key":"10.1002\/humu.23056-BIB0129|humu23056-cit-0129","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","volume":"35","author":"Luan","year":"2012","journal-title":"Brain Dev"},{"key":"10.1002\/humu.23056-BIB0130|humu23056-cit-0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2003.11.004","article-title":"Glucocerebrosidase mutations in subjects with Parkinsonism","volume":"81","author":"Lwin","year":"2004","journal-title":"Mol Genet Metab"},{"key":"10.1002\/humu.23056-BIB0131|humu23056-cit-0131","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1002\/humu.23056-BIB0132|humu23056-cit-0132","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.pjnns.2014.07.005","article-title":"Cognitive impairment in carriers of glucocerebrosidase gene mutation in Parkinson disease patients","volume":"48","author":"Malec-Litwinowicz","year":"2014","journal-title":"Neurol Neurochir Pol"},{"key":"10.1002\/humu.23056-BIB0133|humu23056-cit-0133","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neulet.2009.12.007","article-title":"Association between GBA L444P mutation and sporadic Parkinson's disease from mainland china","volume":"469","author":"Mao","year":"2010","journal-title":"Neurosci Lett"},{"key":"10.1002\/humu.23056-BIB0134|humu23056-cit-0134","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddw129","article-title":"The contribution of mutant GBA to the development of Parkinson disease in Drosophila","author":"Maor","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0135|humu23056-cit-0135","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/hmg\/dds535","article-title":"ITCH regulates degradation of mutant glucocerebrosidase: implications to Gaucher disease","volume":"22","author":"Maor","year":"2013a","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0136|humu23056-cit-0136","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1750-1172-8-140","article-title":"Unfolded protein response in Gaucher disease: from human to drosophila","volume":"8","author":"Maor","year":"2013b","journal-title":"Orphanet J Rare Dis"},{"key":"10.1002\/humu.23056-BIB0137|humu23056-cit-0137","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/dna.1988.7.99","article-title":"Glycosylation and processing of high levels of active human glucocerebrosidase in invertebrate cells using a baculovirus expression vector","volume":"7","author":"Martin","year":"1988","journal-title":"DNA"},{"key":"10.1002\/humu.23056-BIB0138|humu23056-cit-0138","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.4161\/cc.5.12.2865","article-title":"Autophagic defects in aging: looking for an \"emergency exit\"","volume":"5","author":"Massey","year":"2006a","journal-title":"Cell Cycle"},{"key":"10.1002\/humu.23056-BIB0139|humu23056-cit-0139","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0070-2153(05)73007-6","article-title":"Chaperone-mediated autophagy in aging and disease","volume":"73","author":"Massey","year":"2006b","journal-title":"Curr Top Dev Biol"},{"key":"10.1002\/humu.23056-BIB0140|humu23056-cit-0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1002\/humu.23056-BIB0141|humu23056-cit-0141","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1042\/BST20130158","article-title":"Emerging insights into the mechanistic link between alpha-synuclein and glucocerebrosidase in Parkinson's disease","volume":"41","author":"McGlinchey","year":"2013","journal-title":"Biochem Soc Trans"},{"key":"10.1002\/humu.23056-BIB0142|humu23056-cit-0142","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"10.1002\/humu.23056-BIB0143|humu23056-cit-0143","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/cdd.2008.60","article-title":"Itch: a HECT-type E3 ligase regulating immunity, skin and cancer","volume":"15","author":"Melino","year":"2008","journal-title":"Cell Death Differ"},{"key":"10.1002\/humu.23056-BIB0144|humu23056-cit-0144","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4161\/cc.5.16.3260","article-title":"Degradation of p63 by ITCH","volume":"5","author":"Melino","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1002\/humu.23056-BIB0145|humu23056-cit-0145","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1051\/medsci\/2010266-7627","article-title":"[Pharmacological chaperones: a potential therapeutic treatment for conformational diseases]","volume":"26","author":"Mendre","year":"2010","journal-title":"Med Sci (Paris)"},{"key":"10.1002\/humu.23056-BIB0146|humu23056-cit-0146","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1044-579X(02)00099-8","article-title":"The p53-Mdm2 module and the ubiquitin system","volume":"13","author":"Michael","year":"2003","journal-title":"Semin Cancer Biol"},{"key":"10.1002\/humu.23056-BIB0147|humu23056-cit-0147","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.1400768111","article-title":"Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease","volume":"111","author":"Mistry","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0148|humu23056-cit-0148","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/acn3.185","article-title":"Variants associated with Gaucher disease in multiple system atrophy","volume":"2","author":"Mitsui","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1002\/humu.23056-BIB0149|humu23056-cit-0149","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archneurol.2009.72","article-title":"Mutations for Gaucher disease confer high susceptibility to Parkinson disease","volume":"66","author":"Mitsui","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1002\/humu.23056-BIB0150|humu23056-cit-0150","volume-title":"Probe reports from the NIH molecular libraries program [Internet]","author":"Motabar","year":"2010"},{"key":"10.1002\/humu.23056-BIB0151|humu23056-cit-0151","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1371\/journal.pbio.0060026","article-title":"Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis","volume":"6","author":"Mu","year":"2008","journal-title":"PLoS Biol"},{"key":"10.1002\/humu.23056-BIB0152|humu23056-cit-0152","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s007020200013","article-title":"Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients","volume":"109","author":"Muller","year":"2002","journal-title":"J Neural Transm"},{"key":"10.1002\/humu.23056-BIB0153|humu23056-cit-0153","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain"},{"key":"10.1002\/humu.23056-BIB0154|humu23056-cit-0154","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.4161\/auto.29074","article-title":"Glucocerebrosidase deficits in sporadic Parkinson disease","volume":"10","author":"Murphy","year":"2014","journal-title":"Autophagy"},{"key":"10.1002\/humu.23056-BIB0155|humu23056-cit-0155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ceb.2014.04.008","article-title":"Recent technical developments in the study of ER-associated degradation","volume":"29","author":"Nakatsukasa","year":"2014","journal-title":"Curr Opin Cell Biol"},{"key":"10.1002\/humu.23056-BIB0156|humu23056-cit-0156","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with lewy bodies","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1002\/humu.23056-BIB0157|humu23056-cit-0157","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.bbamcr.2013.03.018","article-title":"How early studies on secreted and membrane protein quality control gave rise to the ER associated degradation (ERAD) pathway: the early history of ERAD","volume":"1833","author":"Needham","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/humu.23056-BIB0158|humu23056-cit-0158","volume-title":"Fabry disease: perspectives from 5 years of FOS","author":"Neufeld","year":"2006"},{"key":"10.1002\/humu.23056-BIB0159|humu23056-cit-0159","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"10.1002\/humu.23056-BIB0160|humu23056-cit-0160","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1212\/01.wnl.0000327823.81237.d1","article-title":"Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset","volume":"72","author":"Nichols","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/humu.23056-BIB0161|humu23056-cit-0161","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/mds.26200","article-title":"Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease","volume":"30","author":"Nuzhnyi","year":"2015","journal-title":"Mov Disord"},{"key":"10.1002\/humu.23056-BIB0162|humu23056-cit-0162","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1096\/fasebj.5.3.2001789","article-title":"Saposin proteins: structure, function, and role in human lysosomal storage disorders","volume":"5","author":"O'Brien","year":"1991","journal-title":"FASEB J"},{"key":"10.1002\/humu.23056-BIB0163|humu23056-cit-0163","doi-asserted-by":"crossref","first-page":"42105","DOI":"10.1074\/jbc.M110.172098","article-title":"Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S","volume":"285","author":"Offman","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1002\/humu.23056-BIB0164|humu23056-cit-0164","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nmeth.1591","article-title":"A more efficient method to generate integration-free human IPS cells","volume":"8","author":"Okita","year":"2011","journal-title":"Nat Methods"},{"key":"10.1002\/humu.23056-BIB0165|humu23056-cit-0165","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nchembio.368","article-title":"Endoplasmic reticulum CA2+ increases enhance mutant glucocerebrosidase proteostasis","volume":"6","author":"Ong","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1002\/humu.23056-BIB0166|humu23056-cit-0166","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1872214808666140115111350","article-title":"Treatment of lysosomal storage diseases: recent patents and future strategies","volume":"8","author":"Ortolano","year":"2014","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"10.1002\/humu.23056-BIB0167|humu23056-cit-0167","doi-asserted-by":"crossref","first-page":"10647","DOI":"10.1021\/bi201619z","article-title":"Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-beta-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease","volume":"50","author":"Orwig","year":"2011","journal-title":"Biochemistry"},{"key":"10.1002\/humu.23056-BIB0168|humu23056-cit-0168","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.4161\/auto.25878","article-title":"Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases","volume":"9","author":"Osellame","year":"2013","journal-title":"Autophagy"},{"key":"10.1002\/humu.23056-BIB0169|humu23056-cit-0169","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","article-title":"Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease","volume":"17","author":"Osellame","year":"2013","journal-title":"Cell Metab"},{"key":"10.1002\/humu.23056-BIB0170|humu23056-cit-0170","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/stem.1732","article-title":"Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development","volume":"32","author":"Panicker","year":"2014","journal-title":"Stem Cells"},{"key":"10.1002\/humu.23056-BIB0171|humu23056-cit-0171","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/emmm.200900036","article-title":"Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics","volume":"1","author":"Parenti","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.1002\/humu.23056-BIB0172|humu23056-cit-0172","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.nbd.2009.03.002","article-title":"Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in dementia with Lewy bodies","volume":"34","author":"Parnetti","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1002\/humu.23056-BIB0173|humu23056-cit-0173","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/bj20040198","article-title":"Getting into position: the catalytic mechanisms of protein ubiquitylation","volume":"379","author":"Passmore","year":"2004","journal-title":"Biochem J"},{"key":"10.1002\/humu.23056-BIB0174|humu23056-cit-0174","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00415-013-6923-1","article-title":"Parkinsonism, dementia and glucocerebrosidase mutations","volume":"260","author":"Peall","year":"2013","journal-title":"J Neurol"},{"key":"10.1002\/humu.23056-BIB0175|humu23056-cit-0175","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mds.870100309","article-title":"The anterior olfactory nucleus in Parkinson's disease","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov Disord"},{"key":"10.1002\/humu.23056-BIB0176|humu23056-cit-0176","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","article-title":"Mechanisms underlying ubiquitination","volume":"70","author":"Pickart","year":"2001","journal-title":"Annu Rev Biochem"},{"key":"10.1002\/humu.23056-BIB0177|humu23056-cit-0177","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature13476","article-title":"Sphingolipid lysosomal storage disorders","volume":"510","author":"Platt","year":"2014","journal-title":"Nature"},{"key":"10.1002\/humu.23056-BIB0178|humu23056-cit-0178","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1010335505357","article-title":"Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy","volume":"24","author":"Platt","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1002\/humu.23056-BIB0179|humu23056-cit-0179","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.276.5311.428","article-title":"Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin","volume":"276","author":"Platt","year":"1997","journal-title":"Science"},{"key":"10.1002\/humu.23056-BIB0180|humu23056-cit-0180","doi-asserted-by":"crossref","first-page":"35734","DOI":"10.1074\/jbc.M007300200","article-title":"Recognition and ubiquitination of NOTCH by ITCH, a HECT-type E3 ubiquitin ligase","volume":"275","author":"Qiu","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1002\/humu.23056-BIB0181|humu23056-cit-0181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01243355","article-title":"Prognostic implications of the motor symptoms of Parkinson's disease with respect to clinical, computertomographic and psychometric parameters","volume":"67","author":"Ransmayr","year":"1986","journal-title":"J Neural Transm"},{"key":"10.1002\/humu.23056-BIB0182|humu23056-cit-0182","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","article-title":"LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase","volume":"131","author":"Reczek","year":"2007","journal-title":"Cell"},{"key":"10.1002\/humu.23056-BIB0183|humu23056-cit-0183","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.biocel.2014.05.010","article-title":"Mitophagy mechanisms and role in human diseases","volume":"53","author":"Redmann","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1002\/humu.23056-BIB0184|humu23056-cit-0184","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0378-1119(88)90511-2","article-title":"Differential expression of the human glucocerebrosidase-coding gene","volume":"73","author":"Reiner","year":"1988","journal-title":"Gene"},{"key":"10.1002\/humu.23056-BIB0185|humu23056-cit-0185","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1523\/JNEUROSCI.23-08-03316.2003","article-title":"Parkin binds to alpha\/beta tubulin and increases their ubiquitination and degradation","volume":"23","author":"Ren","year":"2003","journal-title":"J Neurosci"},{"key":"10.1002\/humu.23056-BIB0186|humu23056-cit-0186","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/archneur.59.4.580","article-title":"Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease","volume":"59","author":"Ribeiro","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1002\/humu.23056-BIB0187|humu23056-cit-0187","first-page":"42","article-title":"Anxiety disorders in Parkinson's disease","volume":"96","author":"Richard","year":"2005","journal-title":"Adv Neurol"},{"key":"10.1002\/humu.23056-BIB0188|humu23056-cit-0188","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13311-014-0294-x","article-title":"A GCase chaperone improves motor function in a mouse model of synucleinopathy","volume":"11","author":"Richter","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1002\/humu.23056-BIB0189|humu23056-cit-0189","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00415-008-0720-2","article-title":"Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German study on Epidemiology of Parkinson's Disease with Dementia (GEPAD)","volume":"255","author":"Riedel","year":"2008","journal-title":"J Neurol"},{"key":"10.1002\/humu.23056-BIB0190|humu23056-cit-0190","volume-title":"Probe reports from the NIH molecular libraries program [Internet]","author":"Rogers","year":"2010"},{"key":"10.1002\/humu.23056-BIB0191|humu23056-cit-0191","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity","volume":"14","author":"Ron","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0192|humu23056-cit-0192","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1093\/hmg\/ddq292","article-title":"Interaction between parkin and mutant glucocerebrosidase variants: A possible link between Parkinson disease and Gaucher disease","volume":"19","author":"Ron","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0193|humu23056-cit-0193","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0888-7543(92)90247-P","article-title":"Structure and evolution of the human prosaposin chromosomal gene","volume":"13","author":"Rorman","year":"1992","journal-title":"Genomics"},{"key":"10.1002\/humu.23056-BIB0194|humu23056-cit-0194","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1002\/humu.23056-BIB0195|humu23056-cit-0195","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bcmd.2008.11.002","article-title":"Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease","volume":"42","author":"Sanchez-Olle","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"10.1002\/humu.23056-BIB0196|humu23056-cit-0196","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/0006-291X(89)92728-9","article-title":"Sphingolipid hydrolase activator proteins and their precursors","volume":"165","author":"Sano","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1002\/humu.23056-BIB0197|humu23056-cit-0197","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0198|humu23056-cit-0198","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000335038","article-title":"Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models","volume":"10","author":"Sardi","year":"2012","journal-title":"Neurodegener Dis"},{"key":"10.1002\/humu.23056-BIB0199|humu23056-cit-0199","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/mds.23046","article-title":"Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization","volume":"25","author":"Saunders-Pullman","year":"2010","journal-title":"Mov Disord"},{"key":"10.1002\/humu.23056-BIB0200|humu23056-cit-0200","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles","volume":"12","author":"Sawkar","year":"2005","journal-title":"Chem Biol"},{"key":"10.1002\/humu.23056-BIB0201|humu23056-cit-0201","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0202|humu23056-cit-0202","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00018-005-5437-0","article-title":"Therapeutic strategies to ameliorate lysosomal storage disorders-a focus on Gaucher disease","volume":"63","author":"Sawkar","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"Pt 2","key":"10.1002\/humu.23056-BIB0203|humu23056-cit-0203","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1101\/SQB.1978.042.01.067","article-title":"Amplification of dihydrofolate reductase genes in methotrexate-resistant cultured mouse cells","volume":"42","author":"Schimke","year":"1978","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"10.1002\/humu.23056-BIB0204|humu23056-cit-0204","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.biocel.2005.05.008","article-title":"Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease","volume":"37","author":"Schmitz","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1002\/humu.23056-BIB0205|humu23056-cit-0205","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1042\/BST20130126","article-title":"Chaperone-mediated autophagy: dedicated saviour and unfortunate victim in the neurodegeneration arena","volume":"41","author":"Schneider","year":"2013","journal-title":"Biochem Soc Trans"},{"key":"10.1002\/humu.23056-BIB0206|humu23056-cit-0206","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1385\/MB:34:2:279","article-title":"The unfolded protein response","volume":"34","author":"Schroder","year":"2006","journal-title":"Mol Biotechnol"},{"key":"10.1002\/humu.23056-BIB0207|humu23056-cit-0207","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.wnl.0000345356.40399.eb","article-title":"Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy","volume":"72","author":"Segarane","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/humu.23056-BIB0208|humu23056-cit-0208","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.biocel.2014.07.017","article-title":"Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease","volume":"54","author":"Serra-Vinardell","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1002\/humu.23056-BIB0209|humu23056-cit-0209","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s00216-011-4671-6","article-title":"Inhibitor screening of pharmacological chaperones for lysosomal beta-glucocerebrosidase by capillary electrophoresis","volume":"399","author":"Shanmuganathan","year":"2011","journal-title":"Anal Bioanal Chem"},{"key":"10.1002\/humu.23056-BIB0210|humu23056-cit-0210","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1021\/bi301223f","article-title":"Functional screening of pharmacological chaperones via restoration of enzyme activity upon denaturation","volume":"51","author":"Shanmuganathan","year":"2012","journal-title":"Biochemistry"},{"key":"10.1002\/humu.23056-BIB0211|humu23056-cit-0211","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","article-title":"Paris (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease","volume":"144","author":"Shin","year":"2011","journal-title":"Cell"},{"key":"10.1002\/humu.23056-BIB0212|humu23056-cit-0212","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1002\/humu.23056-BIB0213|humu23056-cit-0213","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2007.06.010","article-title":"Association between Parkinson's disease and glucocerebrosidase mutations in brazil","volume":"14","author":"Spitz","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1002\/humu.23056-BIB0214|humu23056-cit-0214","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0896-6273(03)00084-9","article-title":"Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity","volume":"37","author":"Staropoli","year":"2003","journal-title":"Neuron"},{"key":"10.1002\/humu.23056-BIB0215|humu23056-cit-0215","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.bcp.2006.12.015","article-title":"Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase","volume":"73","author":"Steet","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/humu.23056-BIB0216|humu23056-cit-0216","doi-asserted-by":"crossref","first-page":"e0118771","DOI":"10.1371\/journal.pone.0118771","article-title":"Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology","volume":"10","author":"Sun","year":"2015","journal-title":"PLoS One"},{"key":"10.1002\/humu.23056-BIB0217|humu23056-cit-0217","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/hmg\/ddp580","article-title":"Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394l) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits","volume":"19","author":"Sun","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0218|humu23056-cit-0218","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1194\/jlr.M600239-JLR200","article-title":"Conditional expression of human acid beta-glucosidase improves the visceral phenotype in a Gaucher disease mouse model","volume":"47","author":"Sun","year":"2006","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1002\/humu.23056-BIB0262|humu23056-cit-0262","doi-asserted-by":"crossref","first-page":"e19037","DOI":"10.1371\/journal.pone.0019037","article-title":"Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse","volume":"6","author":"Sun","year":"2011","journal-title":"PLoS One"},{"key":"10.1002\/humu.23056-BIB0219|humu23056-cit-0219","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4240\/wjgs.v5.i7.224","article-title":"Reconstruction of the hepatic artery with the middle colic artery is feasible in distal pancreatectomy with celiac axis resection: a case report","volume":"5","author":"Suzuki","year":"2013","journal-title":"World J Gastrointest Surg"},{"key":"10.1002\/humu.23056-BIB0220|humu23056-cit-0220","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1093\/hmg\/ddv372","article-title":"Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant alpha-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease","volume":"24","author":"Suzuki","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0221|humu23056-cit-0221","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.braindev.2012.12.002","article-title":"Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease","volume":"35","author":"Suzuki","year":"2013","journal-title":"Brain Dev"},{"key":"10.1002\/humu.23056-BIB0222|humu23056-cit-0222","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4137\/PMC.S2332","article-title":"Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities","volume":"3","author":"Suzuki","year":"2009","journal-title":"Perspect Medicin Chem"},{"key":"10.1002\/humu.23056-BIB0223|humu23056-cit-0223","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jcp.20694","article-title":"The CBL family proteins: ring leaders in regulation of cell signaling","volume":"209","author":"Swaminathan","year":"2006","journal-title":"J Cell Physiol"},{"key":"10.1002\/humu.23056-BIB0224|humu23056-cit-0224","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1084\/jem.20100844","article-title":"Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells","volume":"207","author":"Takayama","year":"2010","journal-title":"J Exp Med"},{"key":"10.1002\/humu.23056-BIB0225|humu23056-cit-0225","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/archneur.64.7.1056","article-title":"Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients","volume":"64","author":"Tan","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1002\/humu.23056-BIB0226|humu23056-cit-0226","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.chembiol.2014.06.008","article-title":"ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease","volume":"21","author":"Tan","year":"2014","journal-title":"Chem Biol"},{"key":"10.1002\/humu.23056-BIB0227|humu23056-cit-0227","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbamcr.2004.09.026","article-title":"Ubiquitin, proteasome and parkin","volume":"1695","author":"Tanaka","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/humu.23056-BIB0228|humu23056-cit-0228","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2012-03-417881","article-title":"Induced pluripotent stem cells from cinca syndrome patients as a model for dissecting somatic mosaicism and drug discovery","volume":"120","author":"Tanaka","year":"2012","journal-title":"Blood"},{"key":"10.1002\/humu.23056-BIB0229|humu23056-cit-0229","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/mgme.2001.3201","article-title":"Gaucher disease and Parkinsonism: a phenotypic and genotypic characterization","volume":"73","author":"Tayebi","year":"2001","journal-title":"Mol Genet Metab"},{"key":"10.1002\/humu.23056-BIB0230|humu23056-cit-0230","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/hmg\/dds471","article-title":"Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds","volume":"22","author":"Tiscornia","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0231|humu23056-cit-0231","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbadis.2008.10.016","article-title":"Autophagy: principles and significance in health and disease","volume":"1792","author":"Todde","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/humu.23056-BIB0232|humu23056-cit-0232","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ana.410340412","article-title":"Side of onset of motor symptoms influences cognition in Parkinson's disease","volume":"34","author":"Tomer","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1002\/humu.23056-BIB0233|humu23056-cit-0233","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4155\/fmc.14.41","article-title":"Glucocerebrosidase inhibitors: future drugs for the treatment of Gaucher disease","volume":"6","author":"Trapero","year":"2014","journal-title":"Future Med Chem"},{"key":"10.1002\/humu.23056-BIB0234|humu23056-cit-0234","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/brain\/aws095","article-title":"Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease","volume":"135","author":"Vitner","year":"2012","journal-title":"Brain"},{"key":"10.1002\/humu.23056-BIB0235|humu23056-cit-0235","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-3-7091-1511-4_20","article-title":"Neuronal forms of Gaucher disease","author":"Vitner","year":"2013","journal-title":"Handb Exp Pharmacol"},{"key":"10.1002\/humu.23056-BIB0236|humu23056-cit-0236","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nm.3449","article-title":"RIPK3 as a potential therapeutic target for Gaucher's disease","volume":"20","author":"Vitner","year":"2014","journal-title":"Nat Med"},{"key":"10.1002\/humu.23056-BIB0237|humu23056-cit-0237","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: from stress pathway to homeostatic regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"key":"10.1002\/humu.23056-BIB0238|humu23056-cit-0238","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.chembiol.2011.04.008","article-title":"Lacidipine remodels protein folding and CA2+ homeostasis in Gaucher's disease fibroblasts: a mechanism to rescue mutant glucocerebrosidase","volume":"18","author":"Wang","year":"2011","journal-title":"Chem Biol"},{"key":"10.1002\/humu.23056-BIB0239|humu23056-cit-0239","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1326-9-31","article-title":"Dysregulation of protein trafficking in neurodegeneration","volume":"9","author":"Wang","year":"2014","journal-title":"Mol Neurodegener"},{"key":"10.1002\/humu.23056-BIB0240|humu23056-cit-0240","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/hmg\/ddm324","article-title":"ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones","volume":"17","author":"Wei","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1002\/humu.23056-BIB0241|humu23056-cit-0241","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00146965-200306000-00002","article-title":"Odor identification deficits in diffuse Lewy body disease","volume":"16","author":"Westervelt","year":"2003","journal-title":"Cogn Behav Neurol"},{"key":"10.1002\/humu.23056-BIB0242|humu23056-cit-0242","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/BF00314009","article-title":"Ultrastructural localization of glucocerebrosidase in cultured Gaucher's disease fibroblasts by immunocytochemistry","volume":"234","author":"Willemsen","year":"1987","journal-title":"J Neurol"},{"key":"10.1002\/humu.23056-BIB0243|humu23056-cit-0243","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/jnnp.2006.105940","article-title":"Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese","volume":"78","author":"Wu","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/humu.23056-BIB0244|humu23056-cit-0244","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ymgme.2010.12.014","article-title":"Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models","volume":"102","author":"Xu","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1002\/humu.23056-BIB0245|humu23056-cit-0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.stem.2010.06.009","article-title":"Patient-specific pluripotent stem cells become even more accessible","volume":"7","author":"Yamanaka","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1002\/humu.23056-BIB0246|humu23056-cit-0246","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.stem.2012.05.005","article-title":"Induced pluripotent stem cells: past, present, and future","volume":"10","author":"Yamanaka","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1002\/humu.23056-BIB0247|humu23056-cit-0247","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1073\/pnas.1221046110","article-title":"Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones","volume":"110","author":"Yang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0248|humu23056-cit-0248","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1073\/pnas.1424288112","article-title":"Mutant glucocerebrosidase in Gaucher disease recruits HSP27 to the HSP90 chaperone complex for proteasomal degradation","volume":"112","author":"Yang","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0249|humu23056-cit-0249","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1750-1172-8-151","article-title":"Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease","volume":"8","author":"Yildiz","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1002\/humu.23056-BIB0250|humu23056-cit-0250","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1172\/JCI29224","article-title":"Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility","volume":"116","author":"Yildiz","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1002\/humu.23056-BIB0251|humu23056-cit-0251","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1016\/j.bmc.2006.08.003","article-title":"Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease","volume":"14","author":"Yu","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1002\/humu.23056-BIB0252|humu23056-cit-0252","doi-asserted-by":"crossref","first-page":"13354","DOI":"10.1073\/pnas.240347797","article-title":"Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1","volume":"97","author":"Zhang","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0253|humu23056-cit-0253","doi-asserted-by":"crossref","first-page":"13192","DOI":"10.1073\/pnas.0705637104","article-title":"Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease","volume":"104","author":"Zheng","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/humu.23056-BIB0254|humu23056-cit-0254","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ymgme.2007.03.004","article-title":"Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease","volume":"91","author":"Ziegler","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1002\/humu.23056-BIB0255|humu23056-cit-0255","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/(SICI)1096-9896(199908)188:4<407::AID-PATH377>3.0.CO;2-Z","article-title":"Intracellular transport of acid beta-glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R mutation)","volume":"188","author":"Zimmer","year":"1999","journal-title":"J Pathol"},{"key":"10.1002\/humu.23056-BIB0256|humu23056-cit-0256","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"10.1002\/humu.23056-BIB0257|humu23056-cit-0257","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"}],"container-title":["Human Mutation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhumu.23056","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/humu.23056\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T16:53:45Z","timestamp":1672332825000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/humu.23056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,21]]},"references-count":262,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"URL":"https:\/\/doi.org\/10.1002\/humu.23056","archive":["Portico"],"relation":{},"ISSN":["1059-7794"],"issn-type":[{"value":"1059-7794","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8,21]]}}}